Abstract
Purpose
The purpose of the study is to evaluate the clinical efficacy of initial combined therapy of an alpha-blocker and anticholinergic agent compared with the alpha-blocker alone in patients with benign prostatic hyperplasia (BPH) with overactive bladder (OAB).
Methods
Hundred and fifty-six BPH patients with International Prostate Symptom Score (IPSS) of over 14 (voiding sub-score ≥8 and storage sub-score ≥6) were prospectively included in Korea. Group 1 (n = 69) was the patients who were treated with Tamsulosin 0.2 mg daily alone for 4 weeks and after 8 weeks they were treated with tamsulosin 0.2 mg and solifenacin 5.0 mg daily combination. Group 2 (n = 70) was the patients who were treated initially with tamsulosin 0.2 mg and solifenacin 5.0 mg combination for 12 weeks. Detailed questionnaires were used to assess treatment satisfaction at 4th week and at 12th week of treatment in 2 groups.
Results
Baseline characteristics were not different between the 2 groups. In the 4th week, there was no difference between the 2 groups with regard to IPSS total score and voiding symptom score, although the IPSS storage symptom score was significantly lower in the Group 2 [−2.0 (0.2) △23.8 vs. −3.0 (0.2) △35.7] (P < 0.001). In the 12th week, there was improvement in storage indices such as IPSS storage symptom score, OABSS, and urgency symptoms compared with baseline in each group (P < 0.001). No statistical differences in storage indices observed between the two groups at 12 week.
Conclusions
Earlier treatment with alpha-blocker and anticholinergic agent helped to improve storage symptoms and quality-of-life scores earlier for patients with lower urinary tract symptoms related to BPH and OAB symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Emberton M, Fitzpatrick JM, Garcia-Losa M et al (2008) Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 102:981–986
Peters TJ, Donovan JL, Kay HE et al (1997) The International Continence Society “benign prostatic hyperplasia” study: the bothersomeness of urinary symptoms. J Urol 157:885–889
Lemack GE (2007) Defining the role of overactive bladder treatments in men with lower urinary tract symptoms. Nat Clin Pract Urol 4:174–175
Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562
Kaplan SA, Walmsley K, Te AE et al. (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174: 2273–2275 discussion 2275–2276
Chung BH, Hong SJ, Cho JS et al (2006) Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 97:742–746
Lee E, Yoo KY, Kim Y et al (1998) Prevalence of lower urinary tract symptoms in Korean men in a community-based study. Eur Urol 33:17–21
Blaivas JG, Panagopoulos G, Weiss JP et al (2007) Validation of the overactive bladder symptom score. J Urol 178:543
Coyne KS, Matza LS, Kopp Z et al (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079–1086
Takei M, Homma Y, Japanese Tolterodine Study Group (2005) Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int J Urol 12:456–464
Roehrborn CG, Kaplan SA, Kraus SR et al (2008) Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 72: 1061–1067 discussion 1067
Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306–1314 discussion 1314–1315
Kaplan SA, Roehrborn CG, Rovner ES et al (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296:2319–2328
Kaplan SA, He W, Koltun WD et al (2012) Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Eur Urol 63:158–165
Abrams P, Kaplan S, De Koning Gans HJ et al (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999–1004
Abrams P, Speakman M, Stott M et al (1997) A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80:587–596
Sun YH, Liu ZY, Zhang ZS et al (2011) Long-term efficacy and safety of tamsulosin hydrochloride for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: data from China. Chin Med J 124:56–60
Tsujimura A, Takao T, Okuda H et al (2010) Survey of lower urinary tract symptoms in patients with benign prostatic hyperplasia and usefulness of tamsulosin hydrochloride. Jpn J Urol Surg 23:301–308
Andersson KE (2004) Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3:46–53
Szell EA, Yamamoto T, de Groat WC, Somogyi GT (2000) Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors. Br J Pharmacol 130:1685–1691
Crawford ED, Wilson SS, McConnell JD et al (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422–1427
Kaplan SA, Wein AJ, Staskin DR et al (2008) Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 180:47–54
Yamaguchi O, Kakizaki H, Homma Y et al (2011) Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms—ASSIST, randomized controlled study. Urology 78:126–133
Kaplan SA, McCammon K, Fincher R et al (2009) Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 182:2825–2830
Burgio KL, Locher JL, Goode PS et al (1998) Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 280:1995–2000
Acknowledgments
This study was supported by the grants and drugs from Korea Prostate Bank and Astellas, Korea. Inc.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, S.H., Byun, S.S., Lee, S.J. et al. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol 46, 523–529 (2014). https://doi.org/10.1007/s11255-013-0551-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-013-0551-7